Antithrombotic strategy | Thromboembolic events | ||
---|---|---|---|
Annual incidence rate | Adjusted HR (95%CI) | P value | |
Any OACs cohort | |||
CHA2DS2-VASc of 0–1 | |||
- OACs | 0.16 (0.01–0.90) | 0.13 (0.01–1.49) | 0.100 |
- No OACs | 1.03 (0.41–2.12) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- OACs | 1.52 (1.19–1.91) | 0.74 (0.41–1.34) | 0.740 |
- No OACs | 2.34 (1.55–3.42) | Reference | |
Warfarin cohort | |||
CHA2DS2-VASc of 0–1 | |||
- Warfarin | 0.19 (0.01–1.07) | 0.13 (0.01–1.57) | 0.108 |
- No OACs | 1.03 (0.41–2.12) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- Warfarin | 1.58 (1.23-2.00) | 0.77 (0.43–1.40) | 0.391 |
- No OACs | 2.34 (1.55–3.42) | Reference | |
DOACs cohort | |||
CHA2DS2-VASc of 0–1 | |||
- DOACs | - | - | - |
- No OACs | 1.03 (0.41–2.12) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- DOACs | 0.8 (0.17–2.37) | 0.56 (0.13–2.48) | 0.444 |
- No OACs | 2.34 (1.55–3.42) | Reference |